Wellstar/TMI Imaging System Begins Marketing to Long-Term Care Facilities
06 Janvier 2009 - 1:23AM
Marketwired
Wellstar International, Inc. (OTCBB: WLSI), a provider of
specialized diagnostic software and equipment, announced today that
its wholly-owned subsidiary, Trillennium Medical Imaging ("TMI"),
is ready to begin marketing its thermal imaging system to long-term
care ("LTC") facilities in the United States. National statistics
currently show that the incidence rate of pressure ulcers, commonly
known as bed sores, is up to 28% of the population for those living
in LTC facilities; with many leading experts believing the rate is
even higher.
LTC facilities generally care for patients that are critically
and/or terminally ill, bed-ridden, and that show higher rates of
dementia; all indicators that put an individual at risk for
developing a pressure ulcer. TMI's thermal imaging diagnostic
device will equip care personnel at these facilities with the
ability to objectively identify patterns of injury associated with
the development of pressure ulcers. This kind of early detection
can lead to intervention and even prevention. By identifying the
tissue changes associated with the development of these wounds
prior to skin breakdown, a patient can receive considerably better
care by avoiding pressure ulcer occurrence altogether. When
long-term care facilities can reduce the occurrence of pressure
ulcers, they receive a higher rating in the pay for performance
("P4P") initiative from the Centers for Medicare & Medicaid
Services ("CMS").
Utilizing TMI's thermal imaging system technology will enable an
LTC facility to provide better overall patient care and
significantly lower its pressure ulcer incidence rate. By having
complete documentation of every skin assessment performed, an LTC
facility can mostly curtail its liabilities by protecting itself
against costly lawsuits.
With nearly 16,000 long-term care facilities in the United
States, and an aging population that is increasing in numbers year
after year, TMI has an enormous and largely untouched market to go
after with its revolutionary system. TMI's marketing plan includes
a program where LTC facilities can lease the equipment necessary to
perform skin assessments and store the necessary data. Lease plans
start at a minimal monthly fee of $2,000 per unit. This monthly fee
allows for unlimited imaging, a factor that should help promote
aggressive imaging/assessment programs by these facilities.
Wellstar/TMI CEO, John Antonio, commented: "We have already seen
a positive response to our thermal imaging system among the LTC
facilities we have been engaged with. We expect significant revenue
potential within the LTC market, and the Company anticipates
placing initial units within these facilities sometime within the
first quarter of 2009."
The company has developed its thermal imaging system for various
applications. The TMI technology and software has been approved by
the FDA as an Adjunctive Diagnostic Screening Procedure for early
breast cancer detection, differential diagnoses of pain
dysfunctions (such as Reflex Sympathetic Dystrophy, Neuromuscular
Skeletal Syndromes and neurological disorders), for the early
detection of pressure ulcers, deep tissue injuries, and bedsores,
as well as for orthopedic applications. The company has plans to
market diagnostic systems for all of the above mentioned
applications.
ABOUT WELLSTAR INTERNATIONAL, INC.:
Wellstar International, Inc., through its wholly owned operating
subsidiary Trillennium Medical Imaging, Inc. (TMI), is poised to
become a leading diagnostic company in the health care industry.
TMI has developed and is marketing fully calibrated and functional,
thermal imaging systems that utilize state-of-the-art infrared
technologies and proprietary software to accurately and
cost-effectively measure physiological changes in the human body.
More information on the Company and its unique diagnostic software
and product line is available on Wellstar's corporate Website, by
visiting: www.wellstar.us.
FORWARD-LOOKING STATEMENTS:
This press release contains statements, which may constitute
'forward-looking statements' within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Prospective
investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. Important
factors currently known to management that could cause actual
results to differ materially from those in forward-statements
include fluctuation of operating results, the ability to compete
successfully and the ability to complete before-mentioned
transactions. The company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
CONTACT: Equiti-trend Advisors LLC (800) 953-3350 Toll-Free,
U.S. & Canada (858) 436-3350 Local or International 9:30 a.m.
to 5:00 p.m. EST
Wellstar (CE) (USOTC:WLSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Wellstar (CE) (USOTC:WLSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024